NCT03507166View on ClinicalTrials.gov

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

October 29, 2018

Study Completion Date

October 29, 2018

Conditions
Urothelial CarcinomaAdvanced Cancer
Interventions
DRUG

RC48-ADC

2 mg/kg IV every 2 weeks

Trial Locations (2)

100078

Beijing Cancer Hospital, Beijing

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT03507166 - A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | Biotech Hunter | Biotech Hunter